Literature DB >> 18277458

Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.

Darrell S Rigel1, Abel M Torres, Haines Ely.   

Abstract

BACKGROUND: Using more than one therapeutic approach in the treatment of basal cell carcinomas (BCCs) has the potential to enhance cure rates.
MATERIALS AND METHODS: In this study, 57 nodular and superficial BCCs were curetted without electrodesiccation. One week later, imiquimod 5% cream therapy was initiated once daily 5 times per week for 6 weeks. At 1-year follow-up, 0 of 57 BCCs (0%) had clinical recurrences. Cosmetic results were very good to excellent.
CONCLUSION: Combination therapy with imiquimod 5% cream followed by curettage represents an effective method for treating BCCs with a high cure rate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277458

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

1.  Changes in skin cancer management : a personal perspective.

Authors:  Mark Naylor
Journal:  J Clin Aesthet Dermatol       Date:  2010-04

2.  Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream.

Authors:  Joshua A Zeichner; Rita V Patel; Miriam B Birge
Journal:  J Clin Aesthet Dermatol       Date:  2011-05

3.  Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials.

Authors:  P Severino; J F Fangueiro; S V Ferreira; R Basso; M V Chaud; M H A Santana; A Rosmaninho; E B Souto
Journal:  Clin Transl Oncol       Date:  2013-01-24       Impact factor: 3.405

4.  Management of superficial basal cell carcinoma: focus on imiquimod.

Authors:  Beverly Raasch
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-06-11

5.  Nonsurgical treatment options for Basal cell carcinoma.

Authors:  Mary H Lien; Vernon K Sondak
Journal:  J Skin Cancer       Date:  2011-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.